<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40184">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583256</url>
  </required_header>
  <id_info>
    <org_study_id>V118_05E3</org_study_id>
    <nct_id>NCT02583256</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)</brief_title>
  <official_title>Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine
      Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in
      Trial V118_05. Subjects will receive either the Same or Alternate Type of Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT)</measure>
    <time_frame>Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT)</measure>
    <time_frame>Day 22 and Day 181</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>Day 22 and Day 181</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Serious Adverse Events (SAE)</measure>
    <time_frame>Day 1 - Day 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Adverse Events (AE) leading to withdrawal</measure>
    <time_frame>Day 1 - Day 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with New Onset of Chronic Disease (NOCD)</measure>
    <time_frame>Day 1 - Day 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Day 1 - Day 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Medically attended AEs and associated medications</measure>
    <time_frame>Day 1 - Day 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with solicited AEs</measure>
    <time_frame>Day 1- Day 7 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with unsolicited AEs</measure>
    <time_frame>Day 1- Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1601</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>aQIV-aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with aQIV followed one year later by aQiV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aQIV-QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with aQIV followed one year later by QIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV-aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with QIV followed one year later by aQIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV-QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with QIV followed one year later by QIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aQIV-aQIV</intervention_name>
    <description>aQIV in V118_05 and aQIV in V118_05E3</description>
    <arm_group_label>aQIV-aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aQIV-QIV</intervention_name>
    <description>aQIV in V118_05 and QIV in V118_05E3</description>
    <arm_group_label>aQIV-QIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-aQIV</intervention_name>
    <description>QIV in V118_05 and aQIV in V118_05E3</description>
    <arm_group_label>QIV-aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-QIV</intervention_name>
    <description>QIV in V118_05 and QIV in V118_05E3</description>
    <arm_group_label>QIV-QIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject who has completed their last visit in trial V118_05.

          -  Subject's parent/legal guardian has voluntarily given written informed consent after
             the nature of the study has been explained according to local regulatory
             requirements, prior to study enter

        Exclusion Criteria:

          -  Individuals recently vaccinated against influenza

          -  Subjects with contraindications to receive influenza vaccines

          -  Please contact the site for additional eligibility criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>85 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigational Site- 001</name>
      <address>
        <city>Espoo</city>
        <state>Etelä-Suomen lääni</state>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 002</name>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomen lääni</state>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 003</name>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomen lääni</state>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 004</name>
      <address>
        <city>Järvenpää</city>
        <state>Etelä-Suomen lääni</state>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 005</name>
      <address>
        <city>Kokkola</city>
        <state>Länsi-Suomen lääni</state>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 007</name>
      <address>
        <city>Pori</city>
        <state>Länsi-Suomen lääni</state>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 009</name>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomen lääni</state>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 010</name>
      <address>
        <city>Turku</city>
        <state>Länsi-Suomen lääni</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 006</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 303</name>
      <address>
        <city>Laguna</city>
        <state>Matro Manila</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 304</name>
      <address>
        <city>Muntinlupa</city>
        <state>National Capital Region</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 305</name>
      <address>
        <city>Muntinlupa</city>
        <state>National Capital Region</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 306</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 325</name>
      <address>
        <city>Pathumthani</city>
        <state>Bangkok</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 327</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon [Bangko</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 320</name>
      <address>
        <city>Bangkok</city>
        <state>Samut Prakan</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site- 323</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 8, 2016</lastchanged_date>
  <firstreceived_date>October 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
